Tag Archives: RGLS

Zacks Investment Research Upgrades Regulus Therapeutics (RGLS) to Buy

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The brokerage presently has a $0.75 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 5.63% from the company’s previous close.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

Get Regulus Therapeutics alerts:

Other equities analysts also recently issued reports about the stock. BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the stock a “hold” rating in a report on Thursday, March 8th. Chardan Capital restated a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Finally, B. Riley assumed coverage on Regulus Therapeutics in a research note on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $1.71.

Shares of Regulus Therapeutics stock opened at $0.71 on Wednesday. The stock has a market capitalization of $74.90 million, a price-to-earnings ratio of -0.74 and a beta of 1.72. Regulus Therapeutics has a one year low of $0.70 and a one year high of $0.71.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.15). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 94,318.05% and a negative return on equity of 214.48%. equities analysts predict that Regulus Therapeutics will post -0.59 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. BVF Inc. IL grew its stake in shares of Regulus Therapeutics by 7.9% during the fourth quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock worth $14,533,000 after acquiring an additional 1,025,020 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Regulus Therapeutics by 18.2% during the fourth quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 50,530 shares during the last quarter. Ascend Capital LLC purchased a new stake in shares of Regulus Therapeutics during the fourth quarter worth about $1,053,000. Renaissance Technologies LLC grew its stake in shares of Regulus Therapeutics by 215.7% during the fourth quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 94,000 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Regulus Therapeutics during the first quarter worth about $121,000. Institutional investors and hedge funds own 53.15% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Zacks Investment Research Upgrades Regulus Therapeutics (RGLS) to Buy

Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The brokerage presently has a $0.75 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 5.63% from the company’s previous close.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

Get Regulus Therapeutics alerts:

Other equities analysts also recently issued reports about the stock. BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the stock a “hold” rating in a report on Thursday, March 8th. Chardan Capital restated a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Finally, B. Riley assumed coverage on Regulus Therapeutics in a research note on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $1.71.

Shares of Regulus Therapeutics stock opened at $0.71 on Wednesday. The stock has a market capitalization of $74.90 million, a price-to-earnings ratio of -0.74 and a beta of 1.72. Regulus Therapeutics has a one year low of $0.70 and a one year high of $0.71.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.15). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 94,318.05% and a negative return on equity of 214.48%. equities analysts predict that Regulus Therapeutics will post -0.59 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. BVF Inc. IL grew its stake in shares of Regulus Therapeutics by 7.9% during the fourth quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock worth $14,533,000 after acquiring an additional 1,025,020 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Regulus Therapeutics by 18.2% during the fourth quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 50,530 shares during the last quarter. Ascend Capital LLC purchased a new stake in shares of Regulus Therapeutics during the fourth quarter worth about $1,053,000. Renaissance Technologies LLC grew its stake in shares of Regulus Therapeutics by 215.7% during the fourth quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 94,000 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Regulus Therapeutics during the first quarter worth about $121,000. Institutional investors and hedge funds own 53.15% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)